GenomaLab is a regional pioneer in turnkey stem cell and regenerative medicine laboratories, combining cleanrooms, cell processing tech, cryogenic storage, quality systems, and validated workflows.
The UAE has reached a new milestone in biotechnology and advanced healthcare as GenomaLab Medical LLC, part of GenomaLab Medical Group, becomes the first organization in the Middle East to join the AABB Corporate Partner Program, a prestigious global platform recognizing leadership in blood services, biotherapies, laboratory quality, and patient safety.
This distinction places GenomaLab alongside an elite international network that includes Abbott, Johnson & Johnson, Roche, Terumo, Haemonetics, and Werfen, reinforcing the UAE’s growing role in shaping the future of global life sciences.
“AABB recognition reflects our responsibility to deliver world-class healthcare infrastructure and technologies,” said Dr. A. Shavki, CEO of GenomaLab Medical LLC. “Our mission is to elevate standards across biobanking, plasma, regenerative medicine, and advanced diagnostics—regionally and beyond.”
GenomaLab Medical Group is distinguished by its comprehensive turnkey delivery model, enabling healthcare institutions to work with a single, integrated partner—from concept and design to commissioning, validation, and long-term consumables supply.
As a recognized leader in biobanking and molecular diagnostics, the group offers end-to-end biobank solutions, including facility development, automation, cryogenic storage, laboratory instruments, and validated consumables, supporting precision medicine, genomics, and population health initiatives.
GenomaLab is a regional pioneer in turnkey stem cell and regenerative medicine laboratories, combining cleanrooms, cell processing technologies, cryogenic storage, quality systems, and validated workflows to support advanced therapeutic and research programs.
In the plasma sector, GenomaLab Medical Group provides turnkey plasma collection centers, encompassing facility design, specialized equipment, regulatory compliance, and a comprehensive range of plasma-specific consumables, strengthening safety, traceability, and operational efficiency.
GenomaLab Medical Group supports IVF and reproductive medicine centers through complete turnkey delivery, including embryology laboratories, controlled environments, specialized equipment, and IVF-specific consumables. These solutions are designed to optimize embryo safety, laboratory performance, and clinical outcomes in fertility programs.
Following its IVF expertise, the group delivers GMP-, ISO-, and FDA-compliant cleanroom facilities for laboratories, biobanks, stem cell units, plasma collection centers, and pharmaceutical environments. Each project integrates engineering, qualification, and validation to meet the most stringent international regulatory standards.
Beyond infrastructure, GenomaLab Medical Group maintains a strong portfolio in medical devices and diagnostics, including diabetes management solutions such as Continuous Glucose Monitoring (CGM) systems. A broad range of laboratory, clinical, and diagnostic consumables ensures continuity, quality, and operational excellence for healthcare providers.
GenomaLab Medical Group’s AABB Corporate Partnership, combined with its leadership in IVF, cleanrooms, stem cell and plasma projects, biobanking, medical devices, and consumables, signals a decisive shift in regional healthcare capability.
By uniting international accreditation with turnkey execution and advanced technologies, GenomaLab is helping position the UAE not only as a regional hub, but as a globally aligned leader in life sciences and advanced healthcare delivery.
